Latest Manufacturing News

Page 18 of 335
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026
Botanix’s Sofdra prescriptions rose 5.3% in the September quarter, but flat net revenue and a sharp cash decline have forced a major reset. The company is targeting a roughly 50% reduction in operating expenses while assessing licensing, acquisitions and broader strategic transactions.
Victor Sage
Victor Sage
27 Oct 2026
Viridis Mining and Minerals Limited (ASX:VMM) has moved its Colossus rare earths project into execution after reporting a US$1.20 billion after-tax NPV and securing strategic equity commitments of up to US$120 million. The project still needs definitive debt, offtake and approvals before a Final Investment Decision can unlock full construction.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Range International sharply reduced its quarterly cash outflow while lifting pallet volumes and building a larger rental fleet. But the next phase still depends on a partly subscribed entitlement offer, external funding and several customer opportunities that remain indicative.
Victor Sage
Victor Sage
27 Oct 2026
Pure Foods Tasmania has reported a deeper FY26 loss, negative cash and a material uncertainty over its ability to continue as a going concern. The company says existing facilities may be insufficient from February 2027, with further equity funding uncommitted and a second bank covenant breach possible.
Victor Sage
Victor Sage
27 Oct 2026
NeuroScientific Biopharmaceuticals has secured favourable US FDA feedback on its planned StemSmart Phase 2 trial for refractory Crohn’s disease, while appointing a clinical research partner and advancing manufacturing validation. The company enters the next phase with $3.91 million in cash and a targeted trial start by the end of 2026.
Ada Torres
Ada Torres
27 Oct 2026
Minerals 260 has strengthened the funding and development position of its Bullabulling gold project, reporting approximately A$600 million of pro forma cash and a definitive feasibility study still targeted for Q1 2027. The company has also completed initial grade-control drilling, expanded its mining tenure and advanced village and water infrastructure.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Arovella has moved its off-the-shelf CAR-iNKT therapy ALA-101 into human testing, dosing the first patient in the phase 1 SAPPHIRE trial. The study will now test safety and early signs of activity, with initial data expected in early 2027.
Ada Torres
Ada Torres
27 Oct 2026
Wide Open Agriculture has extended Univar Solutions China’s exclusive distribution rights for its lupin protein products through 2028, preserving a route into the mainland Chinese market. But the agreement is not a purchase order: revenue depends first on WOA restoring commercial supply through contract manufacturing.
Victor Sage
Victor Sage
27 Oct 2026
Argent BioPharma has granted Thai Phytomed International exclusive global commercialisation rights to four cannabis genotypes under a 10-year agreement. The deal preserves Argent’s ownership, but royalties depend on TPI generating profitable sales and securing approvals across multiple markets.
Victor Sage
Victor Sage
27 Oct 2026
AdAlta is nearing two important development milestones for its EW-001 CAR-T therapy, with a US FDA pre-IND meeting scheduled for 4 November and Australian manufacturing runs expected before year-end. The progress comes with encouraging but early Chinese clinical data, while cash of A$0.65 million leaves limited room for delay.
Ada Torres
Ada Torres
26 Oct 2026
Pinnacle Minerals has agreed to acquire an option over five early-stage Utah tungsten projects and plans to raise up to A$1.3 million to fund the move. The deal would reshape the company’s US exposure, board and capital structure, but remains subject to shareholder approval and several title, access and funding conditions.
Maxwell Dee
Maxwell Dee
26 Oct 2026

Browse the archive

Full archive